← Back to Screener
Serina Therapeutics, Inc. (SER)
Price$2.10
Favorite Metrics
Price vs S&P 500 (26W)-64.97%
Price vs S&P 500 (4W)-41.47%
Market Capitalization$25.86M
All Metrics
Book Value / Share (Quarterly)$0.17
Revenue Growth (3Y)63.03%
Cash Flow / Share (Quarterly)$-1.67
Price vs S&P 500 (YTD)5.85%
Gross Margin (TTM)65.07%
Net Profit Margin (TTM)-3498.61%
EPS (TTM)$-1.89
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-1.89
Revenue Growth (5Y)-18.43%
EPS (Annual)$-1.88
ROI (Annual)-1738.07%
Gross Margin (Annual)71.83%
Net Profit Margin (5Y Avg)-17228.27%
Cash / Share (Quarterly)$0.28
Revenue Growth QoQ (YoY)154.90%
ROA (Last FY)-275.96%
Revenue Growth TTM (YoY)3.17%
EBITD / Share (TTM)$-1.86
ROE (5Y Avg)-549.42%
Operating Margin (TTM)-7553.47%
Cash Flow / Share (Annual)$-1.67
P/B Ratio14.69x
P/B Ratio (Quarterly)32.09x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)178.82x
Net Interest Coverage (TTM)-89.13x
ROA (TTM)-219.00%
EPS Incl Extra (Annual)$-1.88
Current Ratio (Annual)1.71x
Quick Ratio (Quarterly)0.94x
3-Month Avg Trading Volume3.15M
52-Week Price Return-60.00%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)198.92x
Asset Turnover (Annual)0.02x
52-Week High$7.92
Operating Margin (5Y Avg)-16851.61%
EPS Excl Extra (Annual)$-1.88
CapEx CAGR (5Y)24.16%
26-Week Price Return-58.08%
Quick Ratio (Annual)0.94x
13-Week Price Return-21.93%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.71x
Enterprise Value$25.75
Revenue / Share Growth (5Y)5.92%
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-14766.92%
Cash / Share (Annual)$0.28
3-Month Return Std Dev235.97%
Gross Margin (5Y Avg)82.27%
Net Income / Employee (TTM)$-2
ROE (Last FY)-1738.07%
Net Interest Coverage (Annual)-66.49x
EPS Basic Excl Extra (Annual)$-1.88
Receivables Turnover (TTM)3.76x
Total Debt / Equity (Quarterly)1.64x
EPS Incl Extra (TTM)$-1.89
Receivables Turnover (Annual)4.98x
ROI (TTM)-583.22%
P/S Ratio (TTM)179.58x
Pretax Margin (5Y Avg)-17280.99%
Revenue / Share (Annual)$0.01
Price vs S&P 500 (52W)-94.63%
Year-to-Date Return9.78%
5-Day Price Return8.81%
EPS Normalized (Annual)$-1.88
ROA (5Y Avg)-232.75%
Net Profit Margin (Annual)-14755.38%
Month-to-Date Return8.25%
EBITD / Share (Annual)$-1.86
Operating Margin (Annual)-17921.54%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-480.73%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.89
P/B Ratio (Annual)69.50x
Pretax Margin (TTM)-3527.08%
Book Value / Share (Annual)$0.07
Price vs S&P 500 (13W)-24.31%
Beta7.97x
Revenue / Share (TTM)$0.01
ROE (TTM)-903.25%
52-Week Low$1.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SERSerina Therapeutics, Inc. | 179.58x | 3.17% | 65.07% | — | $2.10 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases and pain management. The company's proprietary POZ Platform provides controlled drug loading and precise release mechanisms, offering advantages over traditional polymer-based delivery systems. Serina is focused on addressing limitations of existing technologies to enable treatment of challenging small-molecule drugs.